Hennion & Walsh Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Hennion & Walsh Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.75M	Sell	47,113 -412	-0.9%	-$13.3K	0.05%	418
2026 Q1	$1.51M	Buy	47,525 +560	+1%	+$15.3K	0.05%	414
2025 Q4	$1.28M	Buy	46,965 +11,182	+31%	+$295K	0.04%	462
2025 Q3	$926K	Buy	35,783 +14,729	+70%	+$341K	0.03%	527
2025 Q2	$428K	Buy	+21,054	New	+$410K	0.02%	720

Other funds holding CLDX

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hennion & Walsh Asset Management's CLDX Position: Q2 2026 in Review

Hennion & Walsh Asset Management reduced its Celldex Therapeutics (CLDX) stake by 0.87% in Q2 2026, selling an estimated $13.3K and leaving 47,113 shares worth $1.75M. The position accounts for 0.05% of the portfolio, ranked #418.

Hennion & Walsh Asset Management first reported a position in CLDX in Q2 2025 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

Hennion & Walsh Asset Management held 47,113 shares of Celldex Therapeutics worth $1.75M as of Q2 2026.
Hennion & Walsh Asset Management sold 412 Celldex Therapeutics shares in Q2 2026, an estimated $13.3K.
Celldex Therapeutics made up 0.05% of Hennion & Walsh Asset Management's portfolio in Q2 2026, its #418 holding.
Hennion & Walsh Asset Management first reported a position in Celldex Therapeutics in Q2 2025 and has held it in 5 quarters since.
253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Hennion & Walsh Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.